|November 15, 2012|
|07:22 EDT||GILD||Gilead's single tablet Stribild shows positive results in two HIV studies|
Gilead announced two-year results from two pivotal Phase 3 studies evaluating the company’s newest single tablet HIV regimen, StribildTM, among treatment-naïve patients with HIV-1 infection. Data show that Stribild was non-inferior after two years of treatment to two standard of care HIV regimens, Atripla in Study 102 and a protease-based regimen of ritonavir-boosted atazanavir plus Truvada in Study 103. The regimen was approved by the FDA on August 27 for use by treatment-naïve HIV-positive adults based on 48-week results from Studies 102 and 103. A marketing application for Stribild is currently under review in the European Union.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
|August 22, 2014|
|09:36 EDT||GILD||Active equity options trading on open |
Subscribe for More Information
|August 21, 2014|
|07:57 EDT||GILD||Gilead HCV risks overblown, says Bernstein |
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
|August 19, 2014|
|16:00 EDT||GILD||Options Update; August 19, 2014eBay |
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
|09:38 EDT||GILD||Active equity options trading on open |
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD